NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
BioSpace – Sutro Biopharma Maximizes Synergy to Treat Cancer and Preserve Quality of Life
https://www.biospace.com/article/sutro-maximizes-synergy-to-treat-cancer-and-preserve-quality-of-life/ By: Heather McKenzie Published: Jan. 12, 2021 Sutro Biopharma wants to use its antibody-drug conjugates (ADCs) as “laser-guided weapons” against cancer cells...
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Onco’Zine – ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of AML
Peter Hofland, Ph.D. Dec 8, 2020 https://www.oncozine.com/ash-2020-preclinical-models-identifies-cd74-as-potential-target-for-the-treatment-of-aml/ Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1...
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
South San Francisco, Calif., Dec. 8, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
South San Francisco, Calif., Dec. 7, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the American Society of Hematology (ASH) 2020 – Poster Presentation
Download the Presentation, Click Here